Yes, Provera (medroxyprogesterone acetate) commonly causes bleeding and spotting, particularly during initial use.
Bleeding irregularities are an expected and well-documented side effect of medroxyprogesterone acetate (MPA/DMPA), occurring in the majority of users. According to FDA labeling, breakthrough bleeding, spotting, and irregular periods are among the most common adverse reactions associated with Provera 1. The CDC guidelines explicitly state that "amenorrhea and unscheduled spotting or light bleeding is common with DMPA use, and heavy or prolonged bleeding can occur" 2.
Expected Bleeding Patterns
The bleeding pattern typically evolves over time:
- Initial use (first 3-6 months): Irregular spotting and breakthrough bleeding are most common, affecting approximately 69% of users in one study 3
- Continued use: Bleeding irregularities generally decrease with ongoing treatment 2
- Long-term use (≥1 year): Amenorrhea becomes increasingly common, occurring in 52-64% at 12 months and up to 71% at 24 months 4
Clinical Management Algorithm
1. Counseling Before Initiation
Inform the patient that bleeding irregularities are generally not harmful and typically decrease with continued use 2. This pre-treatment counseling has been shown to reduce discontinuation rates 2.
2. If Bleeding Occurs During Treatment
First, rule out underlying pathology if clinically indicated:
- Medication interactions
- Sexually transmitted infections
- Pregnancy
- New pathologic uterine conditions (polyps, fibroids) 2
If no underlying problem is found and patient desires treatment:
For spotting or light bleeding:
For heavy or prolonged bleeding:
- NSAIDs for 5-7 days, OR
- Low-dose combined oral contraceptives or estrogen for 10-20 days (if medically eligible) 2
3. If Bleeding Persists and Is Unacceptable
Counsel on alternative contraceptive methods and offer another method if desired 2.
Important Caveats
- These bleeding irregularities are generally not harmful and do not indicate treatment failure 2
- The FDA label lists "abnormal uterine bleeding (irregular, increase, decrease), change in menstrual flow, breakthrough bleeding, spotting" as expected adverse reactions 1
- For your specific patient with cyclic pelvic pain and premenstrual mastalgia, the bleeding side effect must be weighed against the therapeutic benefit for her pain symptoms
- If bleeding becomes unacceptable despite treatment attempts, discontinuation and alternative therapy should be considered 2
Bottom line: Bleeding with Provera is expected, not exceptional. Reassure the patient this is a known medication effect that typically improves over time, but have a management plan ready if it becomes problematic.